ALB and neoplasm: Finally, the observation that the displacement of the equilibrium of the catechin-BSA complex using a competitive inhibitor of the albumin binding site-I, such as warfarin, highly increases the anti-tumour activity of TMCG, may be useful for the design and formulation of catechin-containing therapies.